Disc Medicine (IRON) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liquidia (LQDA) has outperformed Disc Medicine (IRON) over the past year, gaining 16.4% versus a loss of 13.5%. Over five years, LQDA leads with a +775.6% price change compared with -45.5% for IRON. Liquidia is the larger company by market cap ($2.50 billion vs $2.41 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | LQDA |
|---|---|---|
| Share price | $62.82 | $27.97 |
| Market cap | $2.41B | $2.50B |
| 1-day change | +3.37% | -0.18% |
| YTD return | -23.47% | -18.76% |
| 1-year return | -13.53% | +16.36% |
| 5-year return | -45.55% | +775.63% |
| P/E ratio (TTM) | — | 20.12 |
| Forward P/E | — | 11.63 |
| EPS (TTM) | $-6.58 | $1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $158.32M |
| Revenue growth (YoY) | — | +1031.18% |
| Net income (latest FY) | $-212.18M | $-68.92M |
| Operating margin | — | -32.45% |
| Net margin | — | -43.53% |
| 52-week high | $99.50 | $93.61 |
| 52-week low | $40.00 | $21.94 |
| Distance from 52-week high | -36.86% | -70.12% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +64.23% | +77.58% |
| Average volume | 471.18K | 2.47M |
| Shares outstanding | 38.39M | 89.51M |
| Employees | 165 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed IRON by 29.9 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
IRON vs LQDA FAQ
Which is bigger, Disc Medicine or Liquidia?
Liquidia (LQDA) is larger, with a market capitalization of $2.50B compared with $2.41B for Disc Medicine (IRON).
Which stock has performed better over the past year, IRON or LQDA?
LQDA returned +16.36% over the past 12 months, compared with -13.53% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Liquidia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.